Science201d left
Will the FDA approve intismeran autogene (V940/mRNA-4157)?
Make a prediction
Resolution
Criteria
If the FDA approves intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma for marketing before Apr 1, 2027, then the market resolves to Yes.
Source
Kalshi (kalshi.com)
Closes 201d left
Resolves Jul 1, 2028, 2:00 PM UTC
Discussion
Sign in to join the discussion.